Proven
neurotechnology
built for the
real world
Control Bionics delivers objective, non-invasive neural-signal technology, proven in clinical environments, and built to scale across performance, rehabilitation, medical, research, and assistive communication.
Proven
neurotechnology
built for the
real world
Control Bionics delivers objective, non-invasive neural-signal technology, proven in clinical environments, and built to scale across performance, rehabilitation, medical, research, and assistive communication.
Capability
From signal to actionable insight
The Control Bionics neural-signal platform captures physiological data with medical-grade precision and converts it into measurable, decision-ready outcomes. Built for deployment across clinical, research, and performance environments — and validated where it counts.
Signal acquisition and processing
Real-time analysis and validation
Clinical integration and reporting
Technology
The platform serves distinct markets with precision and measurable outcomes. One underlying technology - four applications.
A platform built for clinical deployment
Medical-grade signal processing meets real-world clinical environments. Designed for integration, validation, and measurable outcomes.
Non-invasive neural signal capture
Physiological data without surgical intervention or implantation. Validated for use in complex clinical environments.
Regulatory pathway established
Cleared for clinical use with ongoing validation across multiple applications — FDA, TGA, and CE registered.
Outcome-focused architecture
Platform designed to deliver decision-ready insights, not only raw data. Built to integrate into clinical and research workflows.
Evidence from clinical and research deployment
Control Bionics technology is validated through research, clinical trials, and real-world deployment across rehabilitation, performance, and research settings.
1,000s of users
Trusted by individuals, clinicians, and organisations across four markets
Government and privately funded
Approved for funding through Medicare, Medicaid, NDIS, and private insurance pathways.
100%
Non-invasive signal acquisition
3 Regulatory clearances
(FDA, TGA, CE)
Latest from our platform
Research, clinical validation and platform developments.
Share Your Colours: Rare Disease Day 2022
Control Bionics is proud to help people all over the world living with rare diseases on Rare Disease Day 2022, and every day.
Combination is Key: New Research Paper Confirms Eye Gaze and EMG Switching Outperforms Traditional Methods
According to the recent paper published by biomedical engineering student Lester Lo at RMIT University, eye gaze combined with EMG switching outperformed traditional eye gaze AAC systems.
ATIA Recorded Session: Expanding Your Universe with Cosmos Connect
Kristin Whitfield, MS, CCC-SLP, recorded a session on the Cosmos Connect and how it can be used to expand your universe. Access the free recorded session as part of ATIA 2022.
Control Bionics Reports 34% Sales Revenue Growth
Featured in a writeup by Kalkine Media, Control Bionics is proud to report a 34% sales revenue growth in the December quarter.
Select your path to neural-signal insights and outcomes
Explore how the platform integrates into clinical workflows and delivers decision-ready outcomes.
Learn more
Discover how researchers are using real-time neural data to power breakthrough studies.
LearnNDIS-registered provider
Control Bionics is a registered NDIS provider. Eligible participants can access our assistive communication devices and neurotechnology solutions through their NDIS plan.